1 Exhibit 1 ------------------------------------------------------------------- ------------- REGENERON PHARMACEUTICALS, INC. (a New York corporation) 7,000,000 Shares of Common Stock PURCHASE AGREEMENT Dated: March 19, 2001 -----...Purchase Agreement • March 20th, 2001 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
REGENERON PHARMACEUTICALS, INC. 5-1/2% Convertible Senior Subordinated Notes due 2008 INDENTUREIndenture • December 4th, 2001 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 10.30 REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 26th, 1997 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
Rights AgreementRights Agreement • October 15th, 1996 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 10.2 WARRANT AGREEMENTWarrant Agreement • August 13th, 1997 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
1 S&S DRAFT REGENERON PHARMACEUTICALS, INC. (a New York corporation) [4,000,000] Shares of Common Stock PURCHASE AGREEMENT Dated: [ ], 2001 TABLE OF CONTENTSPurchase Agreement • March 2nd, 2001 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
ARTICLE IStock Purchase Agreement • March 26th, 1997 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
AGREEMENTPledge Agreement • December 4th, 2001 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
ANDRegistration Rights Agreement • May 15th, 2003 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
REGENERON PHARMACEUTICALS, INC., ISSUER AND U.S. Bank National Association, TRUSTEE INDENTURE DATED AS OF AUGUST 12, 2020 DEBT SECURITIESIndenture • August 12th, 2020 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of August 12, 2020, among REGENERON PHARMACEUTICALS, INC., a New York corporation (the “Company”), and U.S. Bank National Association, as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
ARTICLE I DEFINITIONS 1 1.1. CERTAIN DEFINITIONS 1 ARTICLE II ISSUANCE AND SALE OF SECURITIES 3 2.1 ISSUANCE AND SALE OF SECURITIES 3 ARTICLE III CLOSINGS 3 3.1 CLOSING 3 3.2 PURCHASE OF SECURITIES 4 3.3. DOCUMENTS TO BE DELIVERED 4 3.4 MINIMUM...Securities Purchase Agreement • August 13th, 1997 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
CREDIT AGREEMENT dated as of May 25, 2020 among REGENERON PHARMACEUTICALS, INC. The Lenders Party Hereto GOLDMAN SACHS BANK USA as Administrative Agent GOLDMAN SACHS BANK USA as Sole Bookrunner and Sole Lead ArrangerCredit Agreement • May 29th, 2020 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
CREDIT AGREEMENT (this “Agreement”) dated as of May 25, 2020 among REGENERON PHARMACEUTICALS, INC., a New York corporation, the LENDERS from time to time party hereto and GOLDMAN SACHS BANK USA, as Administrative Agent.
AMENDMENT NO. 3 TO THE MERCK-REGENERON AGREEMENTManufacturing Agreement • March 11th, 2005 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations
1. INTRODUCTION AND CERTAIN DEFINITIONS 1 2. SECURITIES SUBJECT TO THIS AGREEMENT 2 2.1 REGISTRABLE SECURITIES 2 2.2 HOLDERS OF REGISTRABLE SECURITIES 2 2.3 SALE OR TRANSFER OF COMPANY'S COMMON STOCK; LEGEND 3 3. DEMAND REGISTRATIONS 3 3.1 DEMAND BY...Registration Rights Agreement • August 13th, 1997 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
INTRODUCTIONCollaboration Agreement • February 28th, 2006 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
WITNESSETH:License Agreement • August 13th, 2002 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Exhibit 10.25 ------------- February 12, 1998 Leonard S. Schleifer, M.D., Ph.D. President and Chief Executive Officer, Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591-6707 Dear Len: As you know, the Board of...Employment Agreement • March 26th, 1998 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 4.4Registration Rights Agreement • December 4th, 2001 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
ANDStock Purchase Agreement • May 15th, 2003 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
andIndenture • February 9th, 2005 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
CREDIT AGREEMENT dated as of March 19, 2015 among REGENERON PHARMACEUTICALS, INC. REGENERON HEALTHCARE SOLUTIONS, INC. REGENERON GENETICS CENTER LLC REGENERON INTERNATIONAL REGENERON IRELAND HOLDINGS REGENERON IRELAND REGENERON CAPITAL INTERNATIONAL...Credit Agreement • March 23rd, 2015 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
CREDIT AGREEMENT (this “Agreement”) dated as of March 19, 2015 among REGENERON PHARMACEUTICALS, INC., a New York corporation, REGENERON HEALTHCARE SOLUTIONS, INC., a New York corporation, REGENERON GENETICS CENTER LLC, a Delaware limited liability company, REGENERON INTERNATIONAL, an unlimited company incorporated in Ireland, REGENERON IRELAND HOLDINGS, an unlimited company incorporated in Ireland, REGENERON IRELAND, an unlimited company incorporated in Ireland, REGENERON CAPITAL INTERNATIONAL B.V., a besloten vennootschap met beperkte aansprakelijkheid organized under the laws of the Netherlands, the other SUBSIDIARY BORROWERS from time to time party hereto, the LENDERS from time to time party hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent, BANK OF AMERICA, N.A. and U.S. BANK NATIONAL ASSOCIATION, as Co-Syndication Agents, and BARCLAYS BANK PLC, CITIBANK, N.A., CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, FIFTH THIRD BANK and MORGAN STANLEY MUFG LOAN PARTNERS, LLC, as Co-Docum
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.Project Agreement • November 3rd, 2022 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations
In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 03 hereby amends Project Agreement No. 01 as follows:
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. BASE AGREEMENT BETWEEN ADVANCED TECHNOLOGY INTERNATIONAL...Base Agreement • November 5th, 2020 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • South Carolina
This Agreement is entered into between the Advanced Technology International hereinafter referred to as the "Consortium Management Finn (CMF)," and Regeneron Pharmaceuticals. Inc, hereinafter referred to as "Project Agreement Holder." This Agreement constitutes the entire understanding and agreement between the parties with respect to the subject matter hereof and supersedes all prior representations and agreements. It shall not be varied except by an instrument in writing of subsequent date duly executed by an authorized representative of each of the parties. The validity, construction, scope and performance of this Agreement shall be governed by the laws of the state of South Carolina, excluding its choice of laws rules.
INVESTOR AGREEMENT BY AND BETWEENInvestor Agreement • August 6th, 2019 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTOR AGREEMENT (this “Agreement”) is made as of April 8, 2019, by and between Regeneron Pharmaceuticals, Inc. (the “Investor”), a New York corporation with its principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591, and Alnylam Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142.
UNDERWRITING AGREEMENTUnderwriting Agreement • May 29th, 2020 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Regeneron Pharmaceuticals, Inc., a corporation organized under the laws of New York (the “Company”), Sanofi, a French société anonyme (“Sanofi”), and Aventisub LLC, a Delaware limited liability company and wholly owned subsidiary of Sanofi (“Aventisub” and together with Sanofi, the “Selling Shareholders”), confirm their respective agreements with the several underwriters named in Schedule A hereto, acting severally and not jointly (the “Underwriters”), for whom you (in such capacity, the “Representatives”) are acting as representatives, with respect to (i) the sale by the Selling Shareholders of an aggregate of 11,831,496 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) and the purchase by the Underwriters, acting severally and not jointly, of the respective number of shares of Common Stock set forth on Schedule A hereto, and (ii) the grant by the Selling Shareholders, to the Underwriters, acting severally and not jointly, of the option described
EXHIBIT 10.31 COLLABORATION AGREEMENTCollaboration Agreement • March 26th, 1997 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Third Amended and Restated Participation Agreement dated as of March 27, 2023 and effective as of the Restatement Date among Old Saw Mill Holdings LLC, as Lessee, BA Leasing BSC, LLC, as Lessor, Bank of America, N.A., not in its individual capacity,...Participation Agreement • March 29th, 2023 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Third Amended and Restated Participation Agreement (as amended, restated, supplemented, or otherwise modified from time to time, this “Participation Agreement”), dated as of March 27, 2023, and effective as of the Restatement Date, is entered into by and among Old Saw Mill Holdings LLC, a New York limited liability company, as Lessee (together with its successors and permitted assigns, in its capacity as Lessee, the “Lessee”); BA Leasing BSC, LLC, a Delaware limited liability company, as Lessor (together with its successors and permitted assigns, in its capacity as Lessor, the “Lessor”); Bank of America, N.A., not in its individual capacity, except as expressly stated herein, but solely as Administrative Agent (together with its successors and permitted assigns, in its capacity as Administrative Agent, the “Administrative Agent”), and the Persons listed on Schedule II hereto as Rent Assignees (together with their permitted successors, assigns and transferees, each as a Rent Assign
Third Amended and Restated Guaranty dated as of March 27, 2023 and effective as of the Restatement Date made by Regeneron Pharmaceuticals, Inc., as Parent Guarantor, and the Subsidiary Guarantors party hereto from time to timeGuaranty • March 29th, 2023 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Third Amended and Restated Guaranty (as amended, restated, supplemented or otherwise modified from time to time, this “Guaranty”), dated as of March 27, 2023, and effective as of the Restatement Date, is made by (i) Regeneron Pharmaceuticals, Inc., a New York corporation (the “Parent Guarantor”), (ii) each of the undersigned Subsidiaries (as hereinafter defined) of the Parent Guarantor (the “Initial Subsidiary Guarantors” and together with the Parent Guarantor, the “Initial Guarantors”) and (iii) any additional Subsidiaries of the Parent Guarantor which become parties to this Guaranty by executing a supplement hereto in the form attached as Annex I (collectively with the Initial Subsidiary Guarantors, the “Subsidiary Guarantors” and together with the Parent Guarantor, the “Guarantors”) in favor of (a) each Participant (as hereinafter defined) and (b) Bank of America, N.A., not in its individual capacity, except as expressly stated therein, but solely as Administrative Agent (toget
AMENDED AND RESTATED DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT By and Between AVENTIS PHARMACEUTICALS INC. and REGENERON PHARMACEUTICALS, INC. Dated as of November 10, 2009Discovery and Preclinical Development Agreement • June 2nd, 2010 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT (“Agreement”), dated as of November 10, 2009 (the “Effective Date”), is by and between AVENTIS PHARMACEUTICALS INC. (“Sanofi”), a corporation organized under the laws of Delaware, having a principal place of business at 55 Corporate Drive, Bridgewater, New Jersey 08807, an indirect wholly owned subsidiary of Sanofi-Aventis, a company organized under the laws of France with its principal headquarters at 174, avenue de France, 75103 Paris, France (“Sanofi Parent”), and REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591, USA (“Regeneron”) (with each of Sanofi and Regeneron referred to herein individually as a “Party” and collectively as the “Parties”).
As of November 14, 2008 Leonard S. Schleifer, M.D., Ph.D. President and Chief Executive Officer, Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591-6707 Dear Len:Employment Agreement • February 26th, 2009 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
This employment agreement will replace and update the agreement dated December 20, 2002 between Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") and you. The compensation obligations of the Company under this agreement (the "Agreement") will be reduced by any amounts actually paid by any affiliate, subsidiary, and related entity controlled by or under common control with the Company ("Related Entity").
COLLABORATION AGREEMENT By and Between AVENTIS PHARMACEUTICALS INC. and REGENERON PHARMACEUTICALS, INC. Dated as of September 5, 2003Collaboration Agreement • November 12th, 2003 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS COLLABORATION AGREEMENT (“Agreement”), dated as of September 5, 2003 (the “Effective Date”), is by and between AVENTIS PHARMACEUTICALS INC., a corporation organized under the laws of Delaware and having a principal place of business at 200 Crossing Boulevard, Bridgewater, New Jersey 08807 (“Aventis”), and REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”) (with each of Aventis and Regeneron referred to herein individually as a “Party” and collectively as the “Parties”).
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 3...Master Agreement • October 31st, 2024 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 3 (“Amendment No. 3”) to the Master Agreement is entered into and effective as of August 1, 2024 (“Amendment No. 3 Effective Date”) by and between Regeneron Pharmaceuticals, Inc., a corporation organized under the laws of New York (“Regeneron”), and Alnylam Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Alnylam”). All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
NON-EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENTNon-Exclusive License and Material Transfer Agreement • May 4th, 2007 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Non-Exclusive License and Material Transfer Agreement (“Agreement”) is entered into with an effective date as of March 30, 2007 (the “Effective Date”), by and between Astellas Pharma Inc., a Japanese company with a principal place of business located at 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan (“Company”), and Regeneron Pharmaceuticals, Inc. (“Regeneron”), a New York corporation, with a principal place of business located at 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707.
IL-1 ANTIBODY TERMINATION AGREEMENT By and Between NOVARTIS PHARMA AG NOVARTIS PHARMACEUTICALS CORPORATION AND REGENERON PHARMACEUTICALS, INC. Dated as of June 8, 2009Il-1 Antibody Termination Agreement • August 4th, 2009 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS IL-1 ANTIBODY TERMINATION AGREEMENT (“Agreement”), made as of June 8, 2009 (the “Effective Date”), is by and between NOVARTIS PHARMA AG, a corporation organized under the laws of Switzerland and having a principal place of business at Lichtstrasse 35, 4056 Basel, Switzerland (“Novartis”), NOVARTIS PHARMACEUTICALS CORPORATION of One Health Plaza, East Hanover, New Jersey (“NPC”) and REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”) (with each of Novartis and Regeneron referred to herein individually as a “Party” and collectively as the “Parties”, and with NPC being a “Party” to this Agreement for purposes of Section 2 only).
EXHIBIT 10.10.1 AMENDMENT AND AGREEMENT This Amendment and Agreement (this "Amendment") is made as of the 30th of June, 2005. BETWEEN: REGENERON PHARMACEUTICALS, INC. a New York corporation having its principal office at 777 Old Saw Mill River Road,...Focused Collaboration Agreement • August 8th, 2005 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
